Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313452 | 1.00 | NR1H2 (0.47) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL18497462 | 1.00 | NR1H2 (0.47) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL1851895 | 0.91 | MEN1 (0.52) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL1849747 | 0.91 | MEN1 (0.52) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL1851893 | 0.91 | MEN1 (0.52) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL416508 | 0.91 | HPGD (0.51) | NR1H2HPGDKDM4EPKMMAPT | |
| SCHEMBL3713776 | 0.87 | NR1H2 (0.55) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL18814079 | 0.87 | NR1H2 (0.46) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL18814077 | 0.87 | NR1H2 (0.46) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL23006119 | 0.85 | NR1H2 (0.44) | NR1H2HPGDKDM4EPKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463450-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | Bisichem Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| CN-118510770-A | Fused heteroaryl hydroxamic acids as STING agonists | 比西切姆有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023136589-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-20 | — | — | WO | disclosed |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3334728-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-8927724-B2 | Isoxazole beta-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140323459-A1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-10-30 | — | — | US | disclosed |
| WO-2013149136-A1 | ISOXAZOLE β-LACTAMASE INHIBITORS | CUBIST PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | NR1H2 3966/4885HPGD 278/4885KDM4E 2442/4885 |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | NR1H2 3966/4885HPGD 278/4885KDM4E 2442/4885 |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | NR1H2 3966/4885HPGD 278/4885KDM4E 2442/4885 |
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | NR1H2 2031/4885HPGD 2353/4885KDM4E 1778/4885 |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | STING1, IRF3, IFNAR1 | NR1H2 774/4885HPGD 422/4885KDM4E 3757/4885 |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | METAP2, FAP, FOLH1 | NR1H2 3966/4885HPGD 278/4885KDM4E 2442/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | NR1H2 44/4885HPGD 190/4885KDM4E 2261/4885 |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | IL5, HRH2, HRH1 | NR1H2 225/4885HPGD 127/4885KDM4E 2578/4885 |
| US-20140323459-A1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | ALPL, MGAM, PEPD | NR1H2 2875/4885HPGD 596/4885KDM4E 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.